Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [(18)F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Corroyer-Dulmont, Aurélien, Pérès, Elodie A., Petit, Edwige, Guillamo, Jean-Sébastien, Varoqueaux, Nathalie, Roussel, Simon, Toutain, Jérôme, Divoux, Didier, MacKenzie, Eric T., Delamare, Jérôme, Ibazizène, Méziane, Lecocq, Myriam, Jacobs, Andréas H., Barré, Louisa, Bernaudin, Myriam, Valable, Samuel
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3534417/
https://ncbi.nlm.nih.gov/pubmed/23115160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars